Life Extension Skin Care Sale

Life Extension Magazine

LE Magazine May 2004

FDA Approves Deadly Drugs, Delays Lifesaving Therapies

1. Available at: content/nationworld/nation/012204cccanat painkillers.40e6c221.html. Accessed February 27, 2004.

2. Available at: NEWS/2004/NEW01008.htm. Accessed February 27, 2004.

3. Available at: dockets/ac/02/agenda/3882A_Draft.doc. Accessed February 27, 2004.

4. Available at: 1_1/dailynews/7334-1.html. Accessed February 27, 2004.

5. Anand BS, Romero JJ, Sanduja SK, Lichtenberger LM. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol. 1999 Jul; 94(7):1818-22.

6. Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol. 1995 Jul;6(1):48-53.

7. Bonkovsky HL, Kane RE, Jones DP, Galinsky RE, Banner B. Acute hepatic and renal toxicity from low doses of acetamino- phen in the absence of alcohol abuse or malnutrition: evidence for increased suscep- tibility to drug toxicity due to cardiopul- monary and renal insufficiency. Hepatology. 1994 May;19(5):1141-8.

8. Clemmesen JO, Ott P, Dalhoff KP, Astrup LB, Tage-Jensen U, Poulsen HE.Recommendations for treatment of paracetamol poisoning. Ugeskr Laegr. 1996 Nov 25; 158(48):6892-5.

9. Conti M, Malandrino S, Magistretti MJ. Protective activity of silipide on liver damage in rodents. Jpn J Pharmacol. 1992 Dec;60(4):315-21.

10. DeLeve LD, Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity.Pharmacol Ther. 1991 Dec;52(3):287-305.

11. Derby LE, Jick H. Acetaminophen and renal and bladder cancer. Epidemiology. 1996 Jul;7(4):358-62.

12. Dunjic BS, Axelson J, Ar’Rajab A, Larsson K, Bengmark S. Gastroprotective capability of exogenous phosphatidylcholine in experi- mentally induced chronic gastric ulcers in rats. Scand J Gastroenterol. 1993 Jan;28(1):89-94.

13. Gago-Dominguez M., Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of anal- gesics is a risk factor for renal cell carcino- ma. Br J Cancer. 1999 Oct;81(3):542-8.

14. Graudins A, Aaron CK, Linden CH. Overdose of extended-release acetamino- phen. N Engl J Med. 1995 Jul 20;333(3):196.

15. Jaeschke H, Werner C, Wendel A. Disposition and hepatoprotection by phos- phatidyl choline liposomes in mouse liver. Chem Biol Interact. 1987;64(1-2):127-37.

16. Jones AL. Mechanism of action and value of N-acetylcysteine in the treatmentof early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol. 1998;36(4):277-85.

17. Kaye JA, Myers MW, Jick H. Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology. 2001 Nov;12(6):690-4.

18. Kind B, Krahenbuhl S, Wyss PA, Meier-Abt PJ. Clinical-toxicological case (1). Dosage of N-acetylcysteine in acute paracetamol poisoning. Schweiz Rundsch Med Prax. 1996 Aug 2; 85(31-32):935-8.

19. Lieber CS. Role of oxidative stress and antioxidant therapy in alcoholic andnon-alcoholic liver diseases. Adv Pharmacol. 1997;38:601-28.

20. Lieber CS. Alcohol: its metabolism and interaction with nutrients. Annu Rev Nutr. 2000;20:395-430.

21. McLaughlin JK, Blot WJ, Mehl ES, Fraumeni JF Jr. Relation of analgesic use to renal cancer: population-based findings. Natl Cancer Inst Monogr. 1985 Dec;69:217-22.

22. Mitchell T, Needham A. Over-the-counter drug is treatment for Alzheimer's. Life Extension. November 2000:50-5.

23. Price LM, Poklis A, Johnson DE. Fatal acetaminophen poisoning with evidence ofsubendocardial necrosis of the heart. J Forensic Sci. 1991 May;36(3):930-5.

24. Richie JP Jr, Lang CA, Chen TS. Acetaminophen-induced depletion of glu- tathione and cysteine in the aging mouse kidney. Biochem. Pharmacol. 1992 Jul 7;44(1):129-35.

25. Siegers CP, Moller-Hartmann W. Cholestyramine as an antidote against paracetamol-induced hepato- and nephro- toxicity in the rat. Toxicol Lett. 1989 May;47(2):179-84.

26. Uhlig S, Wendel A. Glutathione enhance- ment in various mouse organs and protec- tion by glutathione isopropyl ester against liver injury. Biochem Pharmacol. 1990 Jun 15;39(12):1877-81.

27. Werner C, Wendel A. Hepatic uptake and antihepatotoxic properties of vitamin E and liposomes in the mouse. Chem Biol Interact. 1990;75(1):83-92.

28. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of sily- marin, in mice and its association with enhancement of phase II enzymes: implica- tions in cancer chemoprevention. Carcinogenesis. 1999 Nov;20(11):2101-8.

29. Available at: analgesics/letter.htm. Accessed February 27, 2004.

30. Available at: analgesics/SciencePaper.htm. Accessed February 27, 2004.

31. Available at: dockets/ac/02/transcripts/3882T1.htm. Accessed February 27, 2004.

32. Kaye JA, Myers MW, Jick H. Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology. 2001 Nov;12(6):690-4.

33. Available at: http://www.kidney-cancer- Accessed February 27, 2004.

34. Available at: http://www.kidney-cancer Accessed February 27, 2004.

35. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med. 1985 Aug 1;313(5):292-5.

36. Linet MS, Chow WH, McLaughlin JK, et al. Analgesics and cancers of the renal pelvis and ureter. Int J Cancer. 1995 Jul 4;62(1):15-8.

37. McCredie M, Stewart JH, Day NE. Different roles for phenacetin and parac- etamol in cancer of the kidney and renal pelvis. Int J Cancer. 1993 Jan 21;53(2):245-9.

38. Brunner FP, Selwood NH. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortal- ity. EDTA-ERA Registry Committee. Nephrol Dial Transplant. 1994;9(10):1371-6.

39. Stewart JH, Hobbs JB, McCredie MR. Morphologic evidence that analgesic- induced kidney pathology contributes to the progression of tumors of the renal pelvis. Cancer. 1999 Oct 15;86(8):1576-82.

40. Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med. 1983 Feb 17;308(7):357-62.

41. Rathbun WB, Killen CE, Holleschau AM, Nagasawa HT. Maintenance of hepatic glu- tathione homeostasis and prevention of acetaminophen-induced cataract in mice by L-cysteine prodrugs. Biochem Pharmacol. 1996 May 3;51(9):1111-6.

42. Rathbun WB, Holleschau AM, Cohen JF, Nagasawa HT. Prevention of acetamino- phen- and naphthalene-induced cataract and glutathione loss by CySSME. Invest Ophthalmol Vis Sci. 1996 Apr;37(5):923-9.

43. Nagasawa HT, Shoeman DW, Cohen JF, Rathbun WB. Protection against acetamin- ophen-induced hepatotoxicity by L- CySSME and its N-acetyl and ethyl ester derivatives. J Biochem Toxicol. 1996;11(6):289-95.

44. Zhao C, Shichi H. Prevention of acetamino- phen-induced cataract by a combination of diallyl disulfide and N-acetylcysteine. J Ocul Pharmacol Ther. 1998 Aug;14(4):345-55.

45. Qian W, Shichi H. Cataract formation by a semiquinone metabolite of acetaminophen in mice: possible involvement of Ca(2+)and calpain activation. Exp Eye Res. 2000 Dec;71(6):567-74.

46. Qian W, Shichi H. Acetaminophen pro- duces cataract in DBA2 mice by Ah recep- tor-independent induction of CYP1A2. J Ocul Pharmacol Ther. 2000 Aug;16(4):337-44.

47. Available at: Statistics.asp. Accessed February 27, 2004.

48. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syn- drome. A double-blind, placebo controlled trial. Arzneimittelforschung. 1991 Aug;41(8):773-80.

49. Available at: mag2001/july2001_awsi.html. Accessed February 27, 2004.

50. Ambrozi L, Danielczyk W. Treatment of impaired cerebral function in psychogeri- atric patients with memantine—results of a phase II double-blind study. Pharmacopsychiatry. 1988 May;21(3):144-6.

51. Wilcock G, Mobius HJ, Stoffler A; MMM 500 group. A double-blind, placebo-con- trolled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 Nov;17(6):297-305.

52. Ferris SH. Evaluation of memantine for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2003 Dec;4(12):2305-13.

53. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with mod- erate to severe Alzheimer disease already receiving donepezil: a randomized con- trolled trial. JAMA. 2004 Jan 21;291(3):317-24.

54. Available at: mag2001/july2001_report_brain_01.html. Accessed February 27, 2004.

55. Available at: RLD/rld_labeling_approved_June_2001.html. Accessed February 27, 2004.

56. Available at: appletter/2001/20690s16ltr.pdf. Accessed February 27, 2004.

57. Available at: pages/frontline/shows/prescription/. Accessed February 27, 2004.

58. Available at: pressreleases/Dec98/120298c.htm. Accessed February 27, 2004.

59. Available at: http: // 29-97.html. Accessed February 27, 2004.

60. Available at: pages/frontline/shows/prescription/hazard/. Accessed February 27, 2004.

61. Available at: mag2001/june2001_report_fda.html. Accessed February 27, 2004.

62. Available at: mag2000/sep2000_report_rezulin.html. Accessed February 27, 2004.

63. Available at: article_template.asp?ID=206. Accessed February 27, 2004.

64. Available at: mag2002/jul2002_awsi_01.html. Accessed February 27, 2004.

65. Available at: mag2003/mar2003_cover_effects_02.html. Accessed February 27, 2004.

66. Available at: mag2000/dec2000_awsi.html. Accessed February 27, 2004.

67. Available at: chris/2003/07/22/access_to_medical_treatment_act_amta.htm. Accessed February 27, 2004.

68. Available at: chris/control_tactics.htm. Accessed February 27, 2004.

69. Available at: mag2001/sep2001_awsi.html. Accessed February 27, 2004.

70. Available at: mag2001/july2001_awsi.html. Accessed February 27, 2004.

71. Available at: Accessed February 27, 2004.

72. Available at: mag2001/feb2001_awsi.html. Accessed February 27, 2004.

73. Available at: mag99/may99-cover.html. Accessed February 27, 2004.

74. Available at: pm/2046936740-6743.html. Accessed February 27, 2004.